Brand or generic? new study tests palbociclib in advanced breast cancer
NCT ID NCT07493291
First seen Apr 17, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This study compares the effectiveness and safety of branded palbociclib (Ibrance) versus a local generic version in 100 Iraqi women with advanced hormone receptor-positive, HER2-negative breast cancer. The main goal is to see how long the cancer stays under control (progression-free survival) and how well the tumors shrink. Participants take the drug alongside hormone therapy, and the study aims to provide evidence for affordable treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDK4/6 INHIBITOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anbar cancer center
Ramadi, Al-Anbar Governorate, 10003, Iraq
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.